Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

A 50% decline in a blue-chip share can signal trouble, but not always a broken story. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services.

As a staff writer for Forbes Advisor, SMB, Kristy helps small business owners find the tools they need to keep their businesses running. She uses the experience of managing her own writing and editing ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Blood flows through the blood vessels to deliver the needed oxygen and nutrients to the different cells in the body. The blood clotting process or coagulation is an important process that prevents ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...